Expectation Effects on Emotional Processing

NCT ID: NCT07031804

Last Updated: 2025-06-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

51 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-30

Study Completion Date

2026-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Understanding the mechanisms underlying expectation effects in the affective domain can provide valuable insights into possible therapeutic interventions for mood disorders. Studies have consistently found that expectations can influence emotional experiences. Recently, it has been shown that top-down cognitive control is critical in inducing instruction-based affective placebo effects. However, changes in the emotional system over time not only rely on higher-level cognitive processes but also on more automatic mechanisms shaped by learning and past experiences. How such mechanisms are involved in affective placebo effects is relatively unknown, but is particularly interesting in light of findings showing that previous experiences of successful treatments are an important determinant of placebo responses.

This study aims to investigate the neurobehavioral mechanisms of how expectations and prior experiences modulate emotional processing. Healthy adults (N = 51, 50% women) will be recruited to participate in a cross-over fMRI study involving two conditions: positive expectation induction (placebo) and a control condition with no induced expectations. Participants will perform an emotion classification task under each condition. The investigators hypothesize that positive expectations enhance mood and improve the accuracy of recognizing happy facial expressions. Further, they hypothesize that affective expectations are represented in fMRI signal patterns in networks involved in face perception, emotional processing, and cognitive control.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background:

Research demonstrated that positive expectations are related to a perception bias towards positive information and changes in neural networks of affective processing. However, it's unclear how underlying expectancy effects modulate response biases to emotional inputs. A recent study showed the importance of cognitive control and top-down regulation in expectation effects on emotional processing, mechanisms that may be less effective in cognitively vulnerable individuals, such as those with depression. Research on placebo analgesia indicates that not only such higher level-processes but also lower-level processes play a significant role in placebo effects. How such lower level processes are involved in affective placebo effects is relatively unknown but would be highly relevant given that long-term modulation of the emotional system also relies on computationally less costly bottom-up processes typically shaped by learning and experiences. Therefore, this study aims to investigate the neurobehavioral mechanisms of how expectations and prior experiences modulate emotional processing.

Recruitment plan:

Healthy participants will be recruited through an online advertisement on a voluntary basis. An initial short screening to assess basic eligibility (see inclusion and exclusion criteria) will take place over the phone, followed by an extensive screening on site, including the following questionnaires:

* Demographics
* Education
* Generic rating scale for previous treatment experiences, treatment expectations, and treatment effects (G-EEE)
* Beck Depression Inventory (BDI)

Design:

The study consists of three days: one screening day and two study days. On the screening day, in addition to assessing eligibility, participants will receive a saline nasal spray that is introduced as oxytocin. Treatment expectations will be induced via an established expectation induction protocol that systematically manipulates expectations in the context of face perception. Positive expectations about "oxytocin" will be induced via a video documentary detailing the mechanisms of oxytocin, highlighting its mood-enhancing effects and role in emotional processing. In detail, participants will complete a short training of an emotion classification task, view the video documentary, self-administer the nasal spray, rate their expectations using a visual analogue scale (VAS, from "no expected mood enhancement" to "strong expected mood enhancement"), and then complete the same training again. However, the second training is covertly manipulated and is designed to facilitate the detection of happy facial expressions. At the end of the day they will rate their experience with a VAS (from "experienced no positive mood change" to "experienced a large positive mood change"). This expectation induction combined with the covertly manipulated training is already implemented on the screening day to establish positive prior experiences associated with "oxytocin" and therefore enhance placebo effects on the study days. If a participant does not believe in the treatment on the screening day, they will not be included for the main study.

In a cross-over experiment, on two study days that are one week apart, participants will undergo fMRI scanning. Before scanning, participants will receive a saline nasal spray that is either introduced as oxytocin (placebo condition) or saline (control condition) in a counter-balanced design. Expectations will be reinforced via the video documentary. After the video, participants will receive verbal instructions about their assigned condition for that day (either "oxytocin" or control), self-administer the nasal spray, and rate their expectations. Depending on the assigned condition, participants will then either complete a standard training (control condition) or a covertly manipulated training ("oxytocin" condition). Participants will assess their current mood (using a VAS) at three time points: before nasal spray administration, after the manipulated training and after the fMRI scan. At the end of each study day, participants will rate their experience. While in the scanner, an emotion classification task is performed, in which participants label images of subtle emotional face expressions, varying in emotional intensity, as happy, fearful, or neutral. As a control measure, horizontal gaze trajectories (fixation and gaze shifts patterns) will be recorded using eye-tracking.

Hypotheses:

The investigators will examine the effects of positive expectations on mood state and task accuracy and investigate how positive expectations modulate uni- and multivariate fMRI signal patterns associated with the processing and categorization of emotional stimuli. More specifically, they hypothesize the following:

* Positive expectations enhance mood and improve the accuracy of detecting subtle happy facial expressions.
* fMRI patterns in sensory, affective, and cognitive areas in response to subtle happy faces are more similar to patterns evoked by unambiguous happy face localizers in the positive treatment expectation condition.
* Pattern dissimilarity across happiness intensities decreases in the placebo condition.
* Expectation effects on mood, happy face accuracy, and neural patterns are related to expectation ratings and measures of prior experience induced by the manipulated training.

Analysis plan:

For the behavioral analysis, statistical protocols developed in our lab will be applied, with a main focus on response threshold and sensitivity derived from psychometric functions. The effects of expectation on mood state and task accuracy and post-treatment experience will be assessed using statistical tests from the general linear model framework, including t-tests, repeated measures ANOVA and Pearson correlations. Statistical significance will be assumed based on an alpha value of 0.05. Emotion-specific psychometric response functions will be derived from regressing individual accuracy rates from the placebo condition on the control condition. The psychometric response functions will allow us to disentangle expectation effects with respect to response tendencies (intercept) and perceptual sensitivity (slope).

For the univariate fMRI analysis, a two-level random effects general linear model (GLM) approach will be employed, modeling task-related activity using the hemodynamic response function (HRF). Whole-brain analysis (cluster-level corrected) and a small-volume regions of interest (ROI) approach will be applied (p \< .05 FWE corrected). A multivariate representational similarity analysis (RSA) approach will be used to compare the similarity of fMRI patterns during subtle emotional face presentation with patterns derived from unambiguous emotional face localizers. RSA protocols have previously been developed in our lab.

The here presented study is part of the collaborative research center (CRC) SFB/TRR289 and is funded by the Deutsche Forschungsgemeinschaft (DFG, ID: 422744262).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Expectation Effects on Emotional Processing

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

A cross-over design will be employed by giving a saline nasal spray introduced either as oxytocin or as saline.
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants
Participants will be blinded to the real substance (saline nasal spray).

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo - Control

Participants in this group receive sham oxytocin on the first study day.

Group Type EXPERIMENTAL

Saline Nasal Spray

Intervention Type OTHER

A saline nasal spray will be introduced as oxytocin on the first day (induced positive expectations) and as saline on the second day (no induced positive expectations)

Control - Placebo

Participants in this group receive sham oxytocin on the second study day

Group Type EXPERIMENTAL

Saline Nasal Spray

Intervention Type OTHER

A saline nasal spray will be introduced as saline on the first day (no induced expectations) and as oxytocin on the second day (induced positive expectations)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Saline Nasal Spray

A saline nasal spray will be introduced as saline on the first day (no induced expectations) and as oxytocin on the second day (induced positive expectations)

Intervention Type OTHER

Saline Nasal Spray

A saline nasal spray will be introduced as oxytocin on the first day (induced positive expectations) and as saline on the second day (no induced positive expectations)

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18-35 years
* MRI compatible
* Medical information and signed declaration of consent
* Normal or corrected to normal vision
* German speaking

Exclusion Criteria

* No informed consent
* Current intake of central nervous system active drugs
* Under influence of alcohol
* BDI score above 12
* Significant acute somatic or neurological diseases
* History of psychiatric or neurological disorders
* Pregnancy/ breastfeeding
* Acute nasal diseases or injuries
* fMRI data with strong artefacts or excessive movement will be excluded from analysis
* If a participant does not believe in the treatment on the screening day, they will not be included for the main study days
* If a participant drops out after study day one, they will be excluded from the analysis
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Universitätsklinikum Hamburg-Eppendorf

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Stefanie Brassen

Prof. Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stefanie Brassen, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

Department of Systems Neuroscience, University Hospital Hamburg-Eppendorf, Hamburg, Germany

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Medical Center Hamburg-Eppendorf, Institute of Systems Neuroscience

Hamburg, City state of Hamburg, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Stefanie Brassen, Prof. Dr.

Role: CONTACT

+49 407410 54865

Lena Szabo, M.Sc.

Role: CONTACT

+49 407410 58203

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Stefanie Brassen, Prof. Dr.

Role: primary

+49 407410 54865

References

Explore related publications, articles, or registry entries linked to this study.

Mostauli A, Rauh J, Gamer M, Buchel C, Rief W, Brassen S. Placebo treatment entails resource-dependent downregulation of negative inputs. Sci Rep. 2025 Mar 17;15(1):9088. doi: 10.1038/s41598-025-93589-y.

Reference Type BACKGROUND
PMID: 40097556 (View on PubMed)

Baker J, Gamer M, Rauh J, Brassen S. Placebo induced expectations of mood enhancement generate a positivity effect in emotional processing. Sci Rep. 2022 Mar 29;12(1):5345. doi: 10.1038/s41598-022-09342-2.

Reference Type BACKGROUND
PMID: 35351936 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Exface

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Oxytocin, Emotions and Mirror Neurons
NCT02228031 COMPLETED EARLY_PHASE1
Oxytocin and Resting State fMRI
NCT02689596 COMPLETED NA